Nika Pharmaceuticals, Inc. (NIKA) Latest Developments
Nika Pharmaceuticals (OTCQB: NIKA) has released a report detailing the therapeutic effects of ITV-1 on volunteers with AIDS, cancer, and other diseases. The report highlights specific cases demonstrating the drug's curative effects and its potential applications beyond AIDS treatment.
In parallel developments, Nika Europe has made a second payment of $195,554 for the vial production line and is finalizing clean room design details. The factory construction is expected to be completed by the end of Q2 2025.
Nika Pharmaceuticals (OTCQB: NIKA) ha pubblicato un rapporto che illustra gli effetti terapeutici di ITV-1 su volontari affetti da AIDS, cancro e altre malattie. Il rapporto evidenzia casi specifici che dimostrano gli effetti curativi del farmaco e le sue potenziali applicazioni oltre il trattamento dell'AIDS.
In sviluppi paralleli, Nika Europe ha effettuato un secondo pagamento di $195,554 per la linea di produzione delle fiale ed è in fase di finalizzazione dei dettagli del design della camera sterile. La costruzione della fabbrica dovrebbe essere completata entro la fine del secondo trimestre del 2025.
Nika Pharmaceuticals (OTCQB: NIKA) ha publicado un informe que detalla los efectos terapéuticos de ITV-1 en voluntarios con SIDA, cáncer y otras enfermedades. El informe destaca casos específicos que demuestran los efectos curativos del medicamento y sus posibles aplicaciones más allá del tratamiento del SIDA.
En desarrollos paralelos, Nika Europe ha realizado un segundo pago de $195,554 para la línea de producción de viales y está finalizando los detalles del diseño de la sala limpia. Se espera que la construcción de la fábrica esté completada para finales del segundo trimestre de 2025.
Nika Pharmaceuticals (OTCQB: NIKA)는 AIDS, 암 및 기타 질병에 걸린 자원봉사자들에 대한 ITV-1의 치료 효과를 상세히 설명하는 보고서를 발표했습니다. 이 보고서는 약물의 치유 효과를 입증하는 특정 사례와 AIDS 치료를 넘어서는 잠재적 응용 프로그램을 강조합니다.
병행하여, Nika Europe는 바이알 생산 라인에 대해 $195,554의 두 번째 지급을 완료했으며, 클린룸 설계 세부 사항을 마무리하고 있습니다. 공장 건설은 2025년 2분기 말까지 완료될 것으로 예상됩니다.
Nika Pharmaceuticals (OTCQB: NIKA) a publié un rapport détaillant les effets thérapeutiques de ITV-1 sur des volontaires atteints du SIDA, de cancer et d'autres maladies. Le rapport met en avant des cas spécifiques démontrant les effets curatifs du médicament et ses applications potentielles au-delà du traitement du SIDA.
Dans des développements parallèles, Nika Europe a effectué un second paiement de 195 554 $ pour la ligne de production de flacons et finalise les détails de la conception de la salle blanche. La construction de l'usine devrait être achevée d'ici la fin du deuxième trimestre 2025.
Nika Pharmaceuticals (OTCQB: NIKA) hat einen Bericht veröffentlicht, der die therapeutischen Wirkungen von ITV-1 bei Freiwilligen mit AIDS, Krebs und anderen Krankheiten beschreibt. Der Bericht hebt spezifische Fälle hervor, die die heilenden Wirkungen des Medikaments und seine potenziellen Anwendungen über die Behandlung von AIDS hinaus demonstrieren.
In parallelen Entwicklungen hat Nika Europe eine zweite Zahlung von 195.554 $ für die Produktionslinie von Vials geleistet und finalisiert die Details des Reinraums. Der Bau der Fabrik soll bis Ende des zweiten Quartals 2025 abgeschlossen sein.
- Second payment of $195,554 received from Nika Europe for vial production line
- Factory construction progressing with completion expected by Q2 2025
- ITV-1 shows potential for broader therapeutic applications beyond AIDS
- Specific efficacy data and clinical trial results not disclosed in the report
- Timeline for regulatory approvals and commercialization not specified
HENDERSON, Nev., April 11, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) published a report on the therapeutic effect and potential economic impact of ITV-1. The document contains the company’s findings on the effects of the drug on volunteers suffering from AIDS, cancer and other diseases. It details several examples of the curative effect of ITV-1 and its wider applicability beyond AIDS. You can read the document here or on our website.
NIKA’s partner company, Nika Europe, has made the second
Dimitar Savov, NIKA’s CEO, stated: “Although we had previously published the results of the AIDS clinical trials, I believe that it is important to also share our observations with volunteers outside of the trials to present the impact of ITV-1 beyond pure statistics and into particular cases of people suffering from various diseases who ITV-1 has helped tremendously.”
About Nika Pharmaceuticals, Inc.
Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.
Forward-looking Statement:
This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “expects,” “anticipates,” “intends,” “plan,” “may,” “will,” “would,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.
CONTACT Clifford Redekop, Secretary COMPANY Nika Pharmaceuticals, Inc. PHONE (702)-326-3615 EMAIL info@nikapharmaceuticals.com WEB www.nikapharmaceuticals.com
FAQ
What are the latest developments for NIKA's ITV-1 drug treatment?
When will NIKA's new production facility be completed?
How much did Nika Europe pay for the vial production line?
What diseases can NIKA's ITV-1 potentially treat?
